Avid has one diagnostic that it's already submitted to the Food and Drug Administration, florbetapir, which detects plaques in the brains of patients with Alzheimer's disease.
The real winners if florbetapir is approved are the drugmakers that produce Alzheimer's drugs: Pfizer
Eli Lilly isn't in that group, but it's hoping to be. The company's most advanced drug, semagacestat, crashed and burned in August, but it still has another Alzheimer's drug, solanezumab, in phase 3 development.
Florbetapir could also help drugs in development by limiting the variability in the patient population. Since there isn't a great way to diagnose Alzheimer's, patients who have some other form of dementia inevitably get enrolled in clinical trials.
The diagnostic could also be used to measure disease progression. Both Lilly's solanezumab and rival bapineuzumab, which is being developed by Elan
Eli Lilly is potentially paying $800 million for Avid, but only $300 million is on the line initially with the other $500 million tied to regulatory or commercial milestones. Eli Lilly is a minority owner of Avid through its venture capital arm, so investors should have fairly high confidence that it isn't overpaying.
This purchase isn't going to be the move that saves Eli Lilly from its patent cliff crash, but Avid looks like a nice addition that should make the revenue fall a little less deep.
Interested in keeping track of Eli Lilly as it makes its move into diagnostics? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Eli Lilly.